Kisqali's Impact on Heart Rhythm
Kisqali (ribociclib), a CDK4/6 inhibitor for HR-positive, HER2-negative breast cancer, can prolong the QT interval, raising the risk of torsades de pointes—a potentially fatal heart rhythm disorder. This effect stems from the drug's inhibition of cardiac potassium channels (hERG), which delays ventricular repolarization. Clinical data show QT prolongation in 3-13% of patients, with grade 3/4 cases (corrected QT >500 ms) in about 1-3%.[1][2]
Monitoring and Dose Adjustments
Patients undergo ECGs before starting Kisqali, on day 14 of cycle 1, day 1 of cycle 2, and as clinically indicated. Hold treatment if QTcF exceeds 500 ms or increases >60 ms from baseline; resume at reduced dose after normalization. Avoid in patients with long QT syndrome, severe bradycardia, or ongoing proarrhythmic drugs.[1]
Risk Factors in Breast Cancer Patients
Older age, low electrolytes (hypokalemia, hypomagnesemia), heart failure history, or combo with tamoxifen increase risk. Breast cancer patients often have comorbidities like hypertension or prior anthracycline exposure, amplifying vulnerability. Studies report higher QT changes in those with baseline QTc >450 ms.[2][3]
Clinical Trial Evidence
In MONALEESA trials (phase 3 studies vs. placebo + endocrine therapy), mean QTcF increased 15-20 ms by cycle 2 day 1, stabilizing thereafter. Serious arrhythmias were rare (0.2-0.5%), but one trial halted dosing early in high-risk subsets. No direct increase in sudden cardiac death vs. placebo, though monitoring mitigated events.[2][4]
Comparisons to Other CDK4/6 Inhibitors
Kisqali shows greater QT prolongation than Verzenio (abemaciclib, ~10 ms max increase) or Ibrance (palbociclib, minimal effect), per head-to-head ECG data. This leads to stricter protocols for Kisqali.[3][5]
Patient Management Tips
Supplement electrolytes if low; space ECGs closer in at-risk patients. No patent data links directly to cardiac effects—Kisqali's key patents expire 2034-2035.[6]
[1] Kisqali Prescribing Information, Novartis, 2023. https://www.novartis.com/us-en/sites/novartisus/files/kisqali.pdf
[2] MONALEESA-2/7 Trials, NEJM 2018/2019. https://www.nejm.org/doi/full/10.1056/NEJMoa1713779
[3] JACC CardioOncology Review, 2021. https://www.jacc.org/doi/10.1016/j.jaccao.2021.08.001
[4] ESMO Guidelines, 2022. https://www.esmo.org/guidelines/breast-cancer
[5] FDA Label Comparisons, 2023. https://www.accessdata.fda.gov/drugsatfdadocs/label/
[6] DrugPatentWatch.com. https://www.drugpatentwatch.com/p/tradename/KISQALI